Advances in neoadjuvant immunotherapy for non-small cell lung cancer - Top-Institutions - MDSpire

Advances in neoadjuvant immunotherapy for non-small cell lung cancer

  • By

  • Xuehui Liu

  • Huasheng Li

  • Guangqi Dong

  • Yuyan Liu

  • Maobiao Ran

  • Dongbin Wang

  • June 12, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Trinity St. James’s Cancer Institute
    Trinity St. James’s Cancer Institute

    Dublin, Ireland

    Key Differentiators

    • Oncology

  • #2

    Winship Cancer Institute of Emory University School of Medicine
    Winship Cancer Institute of Emory University School of Medicine

    Atlanta, Georgia

    Key Differentiators

    • Oncology

  • #3

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    Dana-Farber/Brigham and Women’s Hospital
    Dana-Farber/Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #5

    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

    Key Differentiators

    • Oncology

Original Source(s)

Advances in neoadjuvant immunotherapy for non-small cell lung cancer

  • by Xuehui Liu, Huasheng Li, Guangqi Dong, Yuyan Liu, Maobiao Ran, Dongbin Wang

  • June 12, 2026

Related Content

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Exercise interventions for depressive symptoms in adults with lung and digestive cancer: a meta-analysis of randomized controlled trials